Ischemia and reactive oxygen species in sympathetic hyperactivity states: A vicious cycle that can be interrupted by renal denervation?

Current Hypertension Reports

Volumn 15, Issue 4, 2013, Pages 313-320

  Hubens, Lisette E G ^a   Verloop, Willemien L ^a   Joles, Jaap A ^a   Blankestijn, Peter J ^a   Voskuil, Michiel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Comorbidity; Hypertension; RAS; Reactive oxygen species; Renal denervation; Renin angiotensin system; ROS; SNS; Sympathetic hyperactivity; Sympathetic nervous system

Indexed keywords

CATALASE; GLUTATHIONE REDUCTASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; ARTICLE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DENERVATION; KIDNEY ISCHEMIA; MINIMALLY INVASIVE PROCEDURE; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PARAVENTRICULAR THALAMIC NUCLEUS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RETENTION; SOLITARY TRACT NUCLEUS; THERAPY EFFECT;

ANIMALS; DENERVATION; HUMANS; HYPERTENSION; ISCHEMIA; KIDNEY; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84880924702     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0367-y     Document Type: Article

References (87)

1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension. A multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
2. Simplicity HTN-1 Investigators. Catheter-based renal symphathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
3. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity Htn-2 Trial). A randomised controlled trial. Lancet. 2010;376:1903-9.
4. Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J. 2011;19:319-23.
5. Prochnau D, Lucas N, Kuehnert H, et al. Catheter-based renal denervation for drug resistant hypertension by using a standard electrophysiology catheter. EuroIntervention. 2012;7:1077-80.
6. Simonetti G, Spinelli A, Gandini R, et al. Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience. Radiol Med. 2012;117:426-44.
7. Bilge M, Tolunay H, Kurmus O, et al. Percutaneous renal denervation in patients with resistant hypertension-first experiences in Turkey. Radiol Med. 2012;117:426-44.
8. Tsioufis C, Dimitriadis K, Tsiachris D, et al. Catheter-based renal sympathetic denervation for the treatment of resistant hypertension: first experience in Greece with significant ambulatory blood pressure reduction. Hell J Cardiol. 2012;53:237-41.
9. Vase H, Mathiassen ON, Kaltoft A, et al. Catheter-based renal denervation for treatment of resistant hypertension. Dan Med J. 2012;59:A4439.
10. Mabin T, Sapoval M, Cabane V, et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. Eurointervention. 2012;8:57-61.
11. Gewirtz JR, Bisognano JD. Cathether-based renal sympathetic denervation: a targeted approach to resistant hypertension. Cardiol J. 2011;18:97-102.
12. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846-51.
13. Kim KE, Onesti G, Schwartz AB, et al. Hemodynamics of hypertension in chronic end-stage renal disease. Circulation. 1972;46:456-64.
14. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-5.
15. Malpas SC. Sympathetic nervous system overactivity and its role in development of cardiovascular disease. Physiol Res. 2010;90:513-57.
16. Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159-72.
17. Witowski A, Prejbisz A, Plorczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
18. Esler M, Lambert E, Schlaich M. Point: chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol. 2010;109:1996-8.
19. O'Dea K, Esler M, Leonard P, Stockigt J, Nestel P. Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism. 1982;31:896-9.
20. Meredith IT, Friberg P, Jennings GL, et al. Regular exercise lowers renal but not cardiac sympathetic activity in man. Hypertension. 1991;18:575-82.
21. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol. 2010;105:570-6.
22. •• Hayden MR, Sowers KM, Pulakat L, et al. Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus. Cardiorenal Med. 2011;1:193-210. This review is of major importance because it provides evidence for the presence of local RAS in organs affected in sympathetic hyperactivity disease states.
23. Silverthorn DU. Human physiology: an integrated approach. 4th ed. Pearson/Benjamin Cummings; 2009. p. 379-86.
24. Dampney RAL. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994;74:323-64.
25. • Kumagai H, Oshima N, Matsuura T, et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res. 2012;35:132-41. This article is of importance because it provides evidence for AngII as a mediator between local ROS production in the brain and afferent nerve activity.
26. Sobotka PA, Krum H, Böhm M, et al. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012;14:285-92.
27. Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195-201.
28. Reid IA. Interactions between ANGII, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763-78.
29. Hendler NH, Livingston A. The localization over time of exogenous aldosterone and angiotensin II in various organs. Pavlov J Biol Sci. 1978;13:187-93.
30. • Zhang ZH, Yu Y, Kang YM, et al. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol. 2008;294:H1067-74. This article is of importance because it provides evidence for local RAS activity in the brain upon oxidative stress.
31. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51:722-7.
32. Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension. 2002;39:1101-6.
33. Nozawa T, Igawa A, Fujii N, et al. Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Hear Vessel. 2002;16:51-6.
34. Getss RT, Hazlett SM, Sharma SB, et al. Regression of left ventricular hypertrophy after bilateral nephrectomy. Nephrol Dial Transplant. 2006;21:1089-91.
35. •• Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens. 2009;27:1341-9. This review is of major importance because it provides evidence for kidney ischemia as a substrate that initiates sympathetic hyperactivity as well as RAS activity in patients with hypertension.
36. Forman HJ, Fukuto JM, Miller T, et al. The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal. Arch Biochem Biophys. 2008;477:183-95.
37. Savoia C, Burger D, Nishigaki N, et al. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 2011;13:e11.
38. Belmonte SL, Blaxall BC. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res. 2011;109:309-19.
39. Zubcevic J, Waki H, Raizada MK, Paton JF. Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension. 2011;57:1026-33.
40. •• Sedeek M, Hebert RI, Kennedy CR, et al. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens. 2009;18:122-7. This review is of major importance because it provides evidence that hypertension is associated with increased ROS production.
41. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338-49.
42. Touyz RM. Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid Redox Signal. 2005;7:1302-14.
43. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2011;34:5-14.
44. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal. 2008;10:1045-59.
45. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15:1583-606.
46. Goyal MM, Basak A. Human catalase: looking for complete identity. Protein Cell. 2010;1:888-97.
47. Traber MG, Stevens JF. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med. 2011;51:1000-13.
48. •• Montezano AC, Touyz RM. Molecular mechanism of hypertension-reactive oxygen species and antioxidant: a basic science update for the clinician. Can J Cardiol. 2012;28:288-95. This review is of major importance because it gives an overview of all ROS and antioxidants that have been reported to be involved in hypertension in animal and human studies.
49. Török J. Participation of nitric oxide in different models of hypertension. Physiol Res. 2008;57:813-25.
50. Rodrigo R, Prat H, Passalacqua W, et al. Relationship between oxidative stress and essential hypertension. Hypertens Res. 2007;30:1159-67.
51. Ward NC, Hodgson JM, Puddey IB, et al. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med. 2004;36:226-32.
52. Raijmakers MT, Dechend R, Poston I. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension. 2004;44:374-80.
53. Chen K, Xie F, Liu S, et al. Plasma reactive carbonyl species: potential risk factor for hypertension. Free Radic Res. 2011;45:568-74.
54. Murphey LJ, Morrow JD, Sawathiparnich P, et al. Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. Free Radic Biol Med. 2003;35:711-8.
55. Lacy F, O'Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998;16:291-303.
56. Lacy F, Kailasam MT, O'Connor DT, et al. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension. 2000;36:878-84.
57. Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296:R195-200.
58. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NADPH oxidase-sensitive pathways. J Hypertens. 2001;19:1245-54.
59. Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens. 2006;20:149-55.
60. Sugiura T, Dohi Y, Takase H, et al. Increased reactive oxygen metabolites is associated with cardiovascular risk factors and vascular endothelial damage in middle-aged Japanese subjects. Vasc Health Risk Manag. 2011;7:475-82.
61. Vassalle C, Bianchi S, Bianchi F, et al. Oxidative stress as a predictor of cardiovascular events in coronary artery disease patients. Clin Chem Lab Med. 2012;50:1463-8.
62. Iamele L, Fiocchi R, Vernocchi A. Evaluation of an automated spectrophotometric assay for reactive oxygen metabolites in serum. Clin Chem Lab Med. 2002;40:673-6.
63. Vassalle C. An easy and reliable automated method to estimate oxidative stress in the clinical setting. In: Armstrong D, editor. Advanced protocols for oxidative stress in the methods in molecular biology series, vol. 477. Hatfield: Humana Press; 2009. p. 31-9.
64. Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:1-7.
65. Schiffrin EL. Antioxidants in hypertension and cardiovascular disease. Mol Interv. 2010;10:354-62.
66. Hasnain BJ, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? Cleve Clin J Med. 2004;71:327-34.
67. Gupte SA. Targeting the pentose phosphate pathway in syndrome X-related cardiovascular complications. Drug Dev Res. 2010;71:161-7.
68. Lopes HF, Martin KL, Nashar K, et al. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension. 2003;41:422-30.
69. Adams V, Linke A, Krankel N, et al. Impact of regular physical activity on the NADPH oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation. 2005;111:555-60.
70. Chen S, Ge Y, Si J, et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008;74:1128-38.
71. Ye S, Gamburd M, Mozayeni P, et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11:723-8.
72. Grande MT, Pascual G, Riolobos AS, et al. Increased oxidative stress, the renin-angiotensin system, and sympathetic overactivation induce hypertension in kidney androgen-regulated protein transgenic mice. Free Radic Biol Med. 2011;51:1831-41.
73. • Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension. 2010;56:325-30. This review is of major importance because it provides evidence that ROS produced in the target organs of sympathetic activity are involved in the pathogenesis of hypertension.
74. Ye S, Zhong H, Campese VM. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension. 2006;48:309-15.
75. Fujita M, Ando K, Nagae A, Fujita T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt-sensitive hypertension. Hypertension. 2007;50:360-7.
76. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004;95:210-6.
77. Gao L, Wang W, Li YL, et al. Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. Am J Physiol Heart Circ Physiol. 2005;288:H2271-9.
78. Campese VM, Ye S-H, Zhong H. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2005;46:533-8.
79. Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant. 2004;19:342-7.
80. Chan SHH, Chan JYH. Brain stem oxidative stress and its associated signaling in the regulation of sympathetic vasomotor tone. Articles in Press. J Appl Physiol. 2012.
81. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Ren Physiol. 2011;1:F31-9.
82. Fujimoto S, Satoh M, Horike H, et al. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res. 2008;31:305-13.
83. Satoh M, Fujimoto S, Arakawa S, et al. Angiotensin II type I receptor blocker ameliorates uncoupled nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant. 2008;23:3806-13.
84. Namikoshi T, Tomita N, Satoh M, et al. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. Am J Hypertens. 2007;20:1085-91.
85. Nagasu H, Satoh M, Kuwabara A, et al. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant. 2010;25:2889-98.
86. Torp M, Brond L, Nielsen JB, et al. Effects of renal denervation on NKCC2 cotransporter in the thick ascending loop of Henle in rats with congestive heart failure. Acta Physiol. 2012;204:451-9.
87. Torp M, Brond L, Hadrup N, et al. Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending loop of Henle in rats with congestive heart failure. Acta Physiol. 2007;190:339-50.